Not too sure. The trading update confused the hell out of me.
Not surprised on revenue front given the numbers that were thrown out, it's the no change in guidance on EBIT. The industry players have always said the wholesale market survives on cross subsidizing and that ~80% of PBS medicines are unprofitable to distribute. If AZ went direct with their profitable drugs (NPSA statement heavily implies this) then the EBIT impact should be a heavily magnified impact of the revenue impact. Given the industry players have already mostly wound back trading terms and reigned in working capital I wonder what levers they can pull this time as an offset.
Not too sure. The trading update confused the hell out of me....
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SIG (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.92 |
Change
0.055(1.92%) |
Mkt cap ! $2.300B | |||
| Open | High | Low | Value | Volume |
| $2.87 | $2.93 | $2.85 | $8.225M | 2.838M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 61121 | $2.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.92 | 36881 | 23 |
View Market Depth
| Last trade - 13.40pm 03/12/2024 (20 minute delay) ? |
| SIG (ASX) Chart |
